FOLD vs. GERN, LGND, DVAX, PRGO, ALKS, MNKD, IRWD, MDGL, INVA, and OPK
Should you be buying Amicus Therapeutics stock or one of its competitors? The main competitors of Amicus Therapeutics include Geron (GERN), Ligand Pharmaceuticals (LGND), Dynavax Technologies (DVAX), Perrigo (PRGO), Alkermes (ALKS), MannKind (MNKD), Ironwood Pharmaceuticals (IRWD), Madrigal Pharmaceuticals (MDGL), Innoviva (INVA), and OPKO Health (OPK). These companies are all part of the "pharmaceutical preparations" industry.
Geron (NASDAQ:GERN) and Amicus Therapeutics (NASDAQ:FOLD) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, media sentiment, analyst recommendations, institutional ownership, community ranking, earnings and dividends.
Amicus Therapeutics has a net margin of -34.73% compared to Amicus Therapeutics' net margin of -38,730.00%. Amicus Therapeutics' return on equity of -68.16% beat Geron's return on equity.
Amicus Therapeutics has higher revenue and earnings than Geron. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Geron, indicating that it is currently the more affordable of the two stocks.
Geron has a beta of 0.55, indicating that its stock price is 45% less volatile than the S&P 500. Comparatively, Amicus Therapeutics has a beta of 0.8, indicating that its stock price is 20% less volatile than the S&P 500.
Amicus Therapeutics received 37 more outperform votes than Geron when rated by MarketBeat users. Likewise, 73.50% of users gave Amicus Therapeutics an outperform vote while only 69.52% of users gave Geron an outperform vote.
Geron presently has a consensus target price of $6.10, suggesting a potential upside of 60.10%. Amicus Therapeutics has a consensus target price of $17.50, suggesting a potential upside of 82.86%. Given Geron's stronger consensus rating and higher probable upside, analysts plainly believe Amicus Therapeutics is more favorable than Geron.
In the previous week, Amicus Therapeutics had 10 more articles in the media than Geron. MarketBeat recorded 13 mentions for Amicus Therapeutics and 3 mentions for Geron. Amicus Therapeutics' average media sentiment score of 0.68 beat Geron's score of 0.46 indicating that Geron is being referred to more favorably in the media.
73.7% of Geron shares are owned by institutional investors. 3.1% of Geron shares are owned by insiders. Comparatively, 2.2% of Amicus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Summary
Amicus Therapeutics beats Geron on 11 of the 18 factors compared between the two stocks.
Get Amicus Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for FOLD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FOLD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Amicus Therapeutics Competitors List
Related Companies and Tools
